LIMED, Exporting Electronic Medicine for Depression Treatment to the US... "Explosive Growth Expected with FDA Approval"

[Asia Economy Reporter Hyungsoo Park] Electronic medicine specialist Remed announced on the 31st that it has exported the demo device of ‘ALTMS,’ a device for depression treatment, to the United States.

Remed is leading the domestic brain rehabilitation field by continuously investing in new clinical trials to expand indications for additional brain diseases such as stroke, Alzheimer’s, and vascular dementia, in addition to depression.

The ALTMS product is an electronic medicine expected as a next-generation treatment method that induces brain nerve modulation through a strong magnetic field. After long efforts to enter the U.S. market, this achievement came just over five months after receiving additional approval in April 2022, following FDA approval in November 2021.

Remed’s brain rehabilitation business division is the sector with relatively lower sales and export proportions among its three business divisions. Since it deals with the human brain, it requires a long time and cost for research and clinical trials, but it is the most promising growth area in the electronic medicine field.

The export to the United States, the largest single-country market, signals the challenge of selling K-electronic medicine, and explosive growth is expected.

Efforts to enter the U.S. market with the chronic pain treatment NMS (Neural Magnetic Stimulation) device ‘Talent-Pro,’ which received FDA approval last May, are also promising.

Remed CEO Eunhyun Ko introduced, “We supplied Remed’s representative electronic medicine product ALTMS (model name Blossom) to the U.S. company Sebers Medical for preclinical testing.”

He added, “Providing ALTMS for market testing is a very significant first step toward Remed’s full-scale entry into the U.S. market.”

This content was produced with the assistance of AI translation services.